FOI 23/859

Dear

Thank you for your email dated 02 November 2023 in which you requested the ***public assessment reports for Levorol 6.25mg tablets (PL 56809/0015) and Levorol 5mg/ml oral solution (PL 39280/0016).***

We confirm that we hold this information; however, section 21(1) applies as this information is available on our website. We provide details below where you may access this information.

Please find attached the link for the published public assessment report for Levorol 6.25mg tablets (PL 56809/0015) 687475a05186c47516a488033fb184ba78d2e567 (windows.net)

Levorol 5mg/ml oral solution (PL 39280/0016) has been through change of ownership since its first approval and converted to a GB Marketing Authorisation on 01 December 2022, PLGB 56809/0001.
Please find attached the link for the published assessment report for Levorol 5mg/ml oral solution (PLGB 56809/0001) 5aa03bf5ab7baed082babc8e0a9bf9fc6c440c18 (windows.net)

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date you receive this response and addressed to: info@mhra.gov.uk

Please remember to quote the reference number above in any future communications.

If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:

Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Or online via: https://ico.org.uk/make-a-complaint/foi-and-eir-complaints/foi-and-eir-complaints/

Yours sincerely

MHRA Customer Experience Centre
Communications and engagement team